Top 5 Papers
#1
Source: European Commission / Laboratoires Pierre Fabre (PR Newswire) | Authors: Laboratoires Pierre Fabre; based on the Phase 3 BREAKWATER trial | Published: June 22, 2026
Score: 13/20 — Base 8 (major regulatory action) + new standard of care (+3) + colleague engagement on X (@OncoAlert, @DraMartinezLago) (+2) = 13
The European Commission has approved encorafenib (BRAFTOVI) in combination with cetuximab and FOLFOX for the first-line treatment of adult patients with BRAF V600E-mutant metastatic colorectal cancer — the first and only BRAF-targeted regimen authorized in the EU for previously untreated disease. The approval follows a May 2026 positive CHMP opinion and is anchored to the Phase 3 BREAKWATER trial, which met its dual primary endpoints of objective response rate and progression-free survival and also delivered a statistically significant overall survival benefit, reducing the risk of death by 51% versus oxaliplatin-based chemotherapy with or without bevacizumab. BRAF V600E mCRC carries one of the worst prognoses in colorectal cancer, and until now first-line options were standard chemotherapy regimens not tailored to the mutation. This decision moves targeted therapy to the front of the line across Europe and harmonizes EU practice with the US, where the regimen already holds approval. For practicing GI oncologists, the message is clean: BRAF V600E testing must happen up front, because it now changes first-line treatment, not just later lines.
Post angle: BRAF V600E mCRC just changed in Europe. The EC has approved encorafenib + cetuximab + FOLFOX as the FIRST BRAF-targeted 1L regimen in the EU, on a BREAKWATER Phase 3 OS benefit — 51% lower risk of death vs chemo±bev. The practice point: test for BRAF V600E up front, it now drives first-line choice. #CRC #GIOnc #BRAF #PrecisionMedicine
#2
Source: Nature Medicine | Authors: Tian R, … Cao Y (senior); Washington University in St. Louis; UK Biobank + All of Us cohorts | Published: June 22, 2026
Score: 11/20 — Base 9 (Nature Medicine) + retrospective / real-world cohort (+1) + biomarker / precision relevance (adipose aging as a mechanism for early-onset CRC) (+1) = 11; Tier-1 safety-net paper
Why is cancer rising in younger adults? This Nature Medicine study offers a mechanistic clue by linking biological aging — how old your tissues actually are, not your birthday — to early-onset cancer. Among 154,169 young adults in the UK Biobank, the authors found that a composite measure of biological aging (PhenoAge) rose roughly 23% of a standard deviation across successive birth cohorts (1965–1974 vs 1950–1954), meaning more recent generations are biologically older at the same chronological age. Accelerated systemic aging was associated with early-onset solid cancers overall (HR 1.08), a signal driven largely by gastrointestinal and uterine tumors. Most striking for GI oncologists, aging of adipose tissue specifically was tied to early-onset colorectal cancer, with a hazard ratio of 1.60. The findings were validated in 10,262 participants from the US All of Us program. The work reframes the early-onset CRC epidemic not as random bad luck but as a measurable, potentially modifiable consequence of accelerated biological aging — and points to metabolic and adipose biology as where to look for prevention.
Post angle: The early-onset CRC epidemic may have a measurable driver. In 154,169 UK Biobank young adults, biological aging rose ~23% SD across birth cohorts — younger generations are biologically older. Accelerated aging tracked with early-onset solid cancers (HR 1.08), and ADIPOSE aging specifically with early-onset CRC (HR 1.60). Validated in US data. Aging biology, not just luck. #CRC #GIOnc #EarlyOnsetCancer
#3
Source: JAMA Network Open | Authors: Wang X, et al.; West China Hospital, Sichuan University; multicenter | Published: June 1, 2026
Score: 9/20 — Base 5 (JAMA Network Open) + Phase III RCT (+3) + colleague engagement on X (@DraMartinezLago) (+1) = 9
Does radiotherapy still add anything after a proper D2 gastrectomy? This Phase 3 randomized trial says no. Among 620 patients with T4 or node-positive gastric cancer who underwent R0 D2 resection, investigators randomized adjuvant S-1 plus oxaliplatin (SOX) with radiotherapy versus SOX chemotherapy alone. Adding radiotherapy did not improve disease-free survival (3-year DFS hazard ratio 0.98, 95% CI 0.73–1.33, p=0.93) or overall survival (3-year OS HR 0.86, p=0.41), and the 5-year figures echoed the result (DFS 60.0% vs 57.3%; OS 73.7% vs 71.4%). In an era where the CRITICS and ARTIST-2 trials already cast doubt on adjuvant chemoradiotherapy after adequate nodal dissection, this trial adds clean, prospective confirmation: in patients who get a high-quality D2 lymphadenectomy, adjuvant chemotherapy alone is sufficient, and the added toxicity and logistics of radiotherapy are not justified. It is a practice-affirming negative trial that should make oncologists comfortable de-escalating radiotherapy in this setting.
Post angle: Another nail in the coffin for adjuvant radiotherapy after D2 gastrectomy. Phase 3 RCT, n=620, T4/N+ gastric cancer: SOX + RT vs SOX alone showed NO DFS (HR 0.98, p=0.93) or OS benefit. After a good D2 dissection, chemo alone is enough — skip the radiation and its toxicity. Confirms CRITICS/ARTIST-2. #GastricCancer #GIOnc
#4
Source: Oncoimmunology | Authors: Truntzer C, … Ghiringhelli F & Ree AH (senior); Dijon (France) + Oslo (Norway), multicenter | Published: June 20, 2026
Score: 9/20 — Base 5 (Oncoimmunology) + pooled Phase II analysis (+2) + overall survival benefit (+2) = 9
MSS colorectal cancer is the textbook 'cold tumor' that does not respond to immunotherapy — but this pooled analysis suggests the story is more nuanced when chemotherapy and checkpoint blockade are combined up front. Investigators pooled two Phase 2 trials, MEDITREME (durvalumab + tremelimumab + FOLFOX) and METIMMOX (alternating nivolumab and oxaliplatin-based chemotherapy), totaling 130 patients with metastatic MSS CRC, and compared first-line chemoimmunotherapy against chemotherapy alone. Median overall survival was significantly longer with chemoimmunotherapy — not reached versus 15.3 months (HR 0.58, 95% CI 0.36–0.96, p=0.03) — and complete response rates were higher (14% vs 5%), even though progression-free survival did not differ. Critically, the benefit concentrated in patients with high baseline CD8 T-cell infiltration, pointing to a tissue biomarker that might prospectively select the MSS subset most likely to benefit from immunotherapy. These are small, exploratory data and should not change practice on their own, but they keep alive the idea that a biomarker-defined slice of MSS CRC may be immunotherapy-sensitive — a hypothesis that now deserves a properly powered, CD8-selected trial.
Post angle: MSS CRC is the classic 'cold' tumor — but maybe not all of it. Pooled MEDITREME + METIMMOX (n=130): 1L chemoimmunotherapy beat chemo alone on OS (NR vs 15.3 mo, HR 0.58, p=0.03), with more complete responses. The benefit clustered in high baseline CD8 TIL tumors. Small + exploratory, but a CD8-selected MSS trial is overdue. #CRC #mCRC #Immunotherapy #GIOnc
#5
Source: Signal Transduction and Targeted Therapy | Authors: Cao Z, … Zhao YP (senior); Peking Union Medical College Hospital; multicenter (China) | Published: June 22, 2026
Score: 8/20 — Base 6 (Signal Transduct Target Ther) + Phase II (+2) = 8
Locally advanced pancreatic cancer (LAPC) sits in an uncomfortable middle ground — not resectable, but not yet metastatic — and the goal of induction therapy is to control disease and, ideally, convert a subset to surgery. This open-label, multicenter Phase 2 trial tested nab-paclitaxel plus S-1 as induction in 60 patients with LAPC. The combination met its primary endpoint, with a 6-month progression-free survival rate of 71.0%, and produced a median PFS of 11.1 months and median overall survival of 20.2 months (12-month OS 83.3%). Objective response rate was 26.7% with a disease control rate of 90.0%, and 18.3% of patients were converted to surgical resection, including ten R0/R1 resections. Toxicity was manageable and consistent with the known profiles of both agents. This is a single-arm study from Chinese centers and S-1-based regimens are used more widely in Asia than in the West, so the data are hypothesis-generating rather than practice-changing. Still, the conversion-to-resection signal and the survival numbers are encouraging for a disease where durable disease control remains elusive, and the regimen merits comparison against FOLFIRINOX-based induction in a randomized setting.
Post angle: A respectable induction signal in locally advanced pancreatic cancer. Phase 2, n=60: nab-paclitaxel + S-1 hit 71% 6-month PFS (primary endpoint met), mOS 20.2 mo, and converted 18% of patients to surgery (incl. 10 R0/R1). Single-arm, Asian centers, S-1-based — hypothesis-generating, but worth a head-to-head vs FOLFIRINOX induction. #PancreaticCancer #PDAC #GIOnc
Additional Papers of Interest
-
British Journal of Cancer — first dedicated trial of the FGFR inhibitor infigratinib in heavily pretreated FGFR2-amplified gastric/GEJ cancer (a ~5% molecular subset): confirmed ORR 23.8%, median PFS 3.4 mo and median OS 6.7 mo — modest but real single-agent activity that supports FGFR2 amplification as a targetable lesion worth profiling in refractory upper-GI cancer.
-
Nature Communications — Johns Hopkins Phase I of a pooled mutant-KRAS peptide vaccine plus nivolumab + ipilimumab in MSS mCRC met all safety endpoints and induced tumor-specific mKRAS-reactive T cells in 8/12 evaluable patients (75%) — an early but encouraging immunogenicity signal in a tumor type that has resisted checkpoint blockade, complementing the MEDITREME/METIMMOX MSS story above.
-
Lancet Gastroenterology & Hepatology — randomized Phase 2 testing whether a third agent improves the atezo+bev standard in 1L HCC: adding ipilimumab did NOT raise response (ORR 30% vs 27%) and came with 6 treatment-related deaths in the triplet arm, so the trial was stopped before its Phase 3 stage — a clean negative that argues against reflexively intensifying the atezo+bev backbone.
-
Nature Communications — preclinical proof-of-concept: a lipid-nanoparticle cocktail of cytokine plus tumor-antigen mRNAs delivered systemically produced curative responses in 50% of autochthonous (genetically engineered) pancreatic-cancer mouse models — an early but provocative mRNA-immunotherapy strategy for the notoriously cold PDAC microenvironment.
Back to all digests